Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally.
Excellent balance sheet with limited growth.
Share Price & News
How has Corindus Vascular Robotics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CVRS's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: CVRS exceeded the US Medical Equipment industry which returned 28.4% over the past year.
Return vs Market: CVRS exceeded the US Market which returned 24.7% over the past year.
Price Volatility Vs. Market
How volatile is Corindus Vascular Robotics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
8 months ago | Simply Wall StDoes Corindus Vascular Robotics, Inc.'s (NYSEMKT:CVRS) CEO Pay Matter?
8 months ago | Simply Wall StCan You Imagine How Chuffed Corindus Vascular Robotics's (NYSEMKT:CVRS) Shareholders Feel About Its 190% Share Price Gain?
9 months ago | Simply Wall StCould The Corindus Vascular Robotics, Inc. (NYSEMKT:CVRS) Ownership Structure Tell Us Something Useful?
Is Corindus Vascular Robotics undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Corindus Vascular Robotics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Corindus Vascular Robotics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Examine Corindus Vascular Robotics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Corindus Vascular Robotics regulatory filings.
- Explore potentially undervalued companies in the Healthcare industry.
How is Corindus Vascular Robotics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CVRS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CVRS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CVRS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CVRS's revenue (42.5% per year) is forecast to grow faster than the US market (7.5% per year).
High Growth Revenue: CVRS's revenue (42.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CVRS's Return on Equity is forecast to be high in 3 years time
How has Corindus Vascular Robotics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CVRS is currently unprofitable.
Growing Profit Margin: CVRS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CVRS is unprofitable, and losses have increased over the past 5 years at a rate of -12.5% per year.
Accelerating Growth: Unable to compare CVRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CVRS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31%).
Return on Equity
High ROE: CVRS has a negative Return on Equity (-198.27%), as it is currently unprofitable.
How is Corindus Vascular Robotics's financial position?
Financial Position Analysis
Short Term Liabilities: CVRS's short term assets ($39.7M) exceed its short term liabilities ($13.2M).
Long Term Liabilities: CVRS's short term assets ($39.7M) exceed its long term liabilities ($11.7M).
Debt to Equity History and Analysis
Debt Level: CVRS's debt to equity ratio (80.5%) is considered high.
Reducing Debt: CVRS's debt to equity ratio has reduced from 484.7% to 80.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CVRS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CVRS has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of -6.2% each year.
What is Corindus Vascular Robotics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CVRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CVRS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CVRS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CVRS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CVRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Toland (49yo)
Mr. Mark J. Toland has been the Chief Executive Officer, President and Director of Corindus Vascular Robotics, Inc. since March 7, 2016. Mr. Toland joined Corindus from Boston Scientific Corporation, a glo ...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD2.19M) is about average for companies of similar size in the US market ($USD2.53M).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
|CEO, President & Director||3.58yrs||US$2.19m||no data|
|CFO, Senior VP||5.17yrs||US$568.37k||no data|
|Chief Operating Officer||3.58yrs||US$1.04m||no data|
|Senior Vice President of Human Resources||3.5yrs||no data||no data|
|Chief Medical Officer of Cardiovascular||3.17yrs||no data||no data|
|Chief Medical Officer of Neuroendovascular||1.25yrs||no data||no data|
|External Consultant & Executive Advisor||3.5yrs||no data||no data|
Experienced Management: CVRS's management team is considered experienced (3.5 years average tenure).
|CEO, President & Director||3.58yrs||US$2.19m||no data|
|Independent Director||1.58yrs||US$48.06k||0.041% $364.5k|
|Independent Chairman of the Board||5.17yrs||no data||no data|
|Independent Director||1.58yrs||US$48.89k||0.038% $335.5k|
|Independent Director||2.58yrs||US$60.00k||0.13% $1.2m|
|Independent Director||5.17yrs||US$67.00k||0.045% $403.1k|
|Independent Director||3.58yrs||US$59.00k||0.033% $296.4k|
Experienced Board: CVRS's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.
Corindus Vascular Robotics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Corindus Vascular Robotics, Inc.
- Ticker: CVRS
- Exchange: AMEX
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$891.087m
- Shares outstanding: 208.69m
- Website: https://www.corindus.com
Number of Employees
- Corindus Vascular Robotics, Inc.
- 309 Waverley Oaks Road
- Suite 105
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CVRS||AMEX (NYSE MKT LLC)||Yes||New Common Stock||US||USD||Aug 2014|
|CR3||DB (Deutsche Boerse AG)||Yes||New Common Stock||DE||EUR||Aug 2014|
Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures. Its CorPath system allows the physician to perform procedures with a control console located within an interventional cockpit; and CorPath GRX system enables the precise robotic-assisted control of guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/30 00:29|
|End of Day Share Price||2019/10/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.